[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity

Rhea-AI Filing Summary

Galectin Therapeutics Inc. director and more than 10% owner associated with 10X Fund, L.P. reported recent changes in holdings. On 11/24/2025, 24,000 shares of common stock were transferred in an in-kind distribution to a withdrawing limited partner of 10X Fund, L.P., with no consideration received, which is described as exempt from short-swing profit rules. On 12/16/2025, 30,681 common shares were sold in multiple transactions at a weighted average price of $6.66 per share, with individual trade prices ranging from $6.64 to $6.69. After these transactions, the reporting entities show beneficial ownership of 5,614,457 Galectin Therapeutics shares held directly by 10X Fund, L.P., with 10X Capital Management, LLC and James C. Czirr reporting potential indirect ownership through their roles.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

10X Fund, L.P.

(Last) (First) (Middle)

545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)

ATLANTA, GA 30324

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		J(1)	V	24,000	D	(1)	5,645,138	D(2)
Common Stock	12/16/2025		S		30,681	D	$6.66(3)	5,614,457	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

10X Fund, L.P.

(Last) (First) (Middle)

545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)

ATLANTA, GA 30324

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

10X Capital Management, LLC

(Last) (First) (Middle)

545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)

ATLANTA, GA 30324

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

CZIRR JAMES C

(Last) (First) (Middle)

4908 SOUTH ASHTON COURT

(Street)

SPOKANE WA 99223

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law.

2. 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

3. The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

	/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP	12/18/2025
	/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC	12/18/2025
	/s/ James C. Czirr, Individually	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Galectin Therapeutics (GALT) report in this filing?

The filing reports two transactions in Galectin Therapeutics common stock: an in-kind distribution of 24,000 shares on 11/24/2025 and an open market sale of 30,681 shares on 12/16/2025.

Who is the reporting person in this Galectin Therapeutics (GALT) insider filing?

The reporting group includes 10X Fund, L.P., its general partner 10X Capital Management, LLC, and James C. Czirr, who is identified as a director and more than 10% owner of Galectin Therapeutics.

How many Galectin Therapeutics (GALT) shares were sold and at what price?

On 12/16/2025, the reporting person sold 30,681 shares of Galectin Therapeutics common stock in multiple transactions at a weighted average price of $6.66 per share, with individual sale prices ranging from $6.64 to $6.69.

What is the size of the reporting persons remaining Galectin Therapeutics (GALT) holdings?

Following the reported transactions, 5,614,457 shares of Galectin Therapeutics common stock are shown as beneficially owned, held directly by 10X Fund, L.P..

What was the 24,000-share transaction reported for Galectin Therapeutics (GALT)?

The 24,000 shares reported on 11/24/2025 were distributed as an in-kind distribution to a withdrawing limited partner of 10X Fund, L.P. The filing states that 10X Fund, L.P. received no consideration and that this distribution is treated as not constituting a sale under applicable law.

How is beneficial ownership of Galectin Therapeutics (GALT) shares described for the reporting entities?

The filing states that 10X Fund, L.P. has direct beneficial ownership of the reported securities. 10X Capital Management, LLC, as general partner, and James C. Czirr, as manager, may be deemed to have indirect beneficial ownership but each disclaims beneficial ownership except to the extent of any pecuniary interest.